N/A
N=40
The Study of Gut Associated Lymphocytes in HIV and HCV/HIV Co-infected Patients
HIV · Hepatitis C, Chronic · HCV Coinfection
Bottom Line
View on ClinicalTrials.gov: NCT01335230 ↗Enrolled (actual)
40
Serious AEs
0.0%
Results posted
Aug 2014
Primary outcome: Primary: Exploring the Role of Gut-associated Th17 in Microbial Translocation in HIV and HCV/HIV Coinfected Patients. — 5.8; 5.84; 5.84; 6.9 relative expression levels
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- —
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of Cincinnati
- Primary completion
- Jan 2013
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Exploring the Role of Gut-associated Th17 in Microbial Translocation in HIV and HCV/HIV Coinfected Patients. |
5.8; 5.84; 5.84; 6.9 | — |
Summary
The purpose of this research study is to explore what role immune cells within the gut (the sigmoid colon) have locally and on the immune system of patients infected with HCV, HIV or HCV/ HIV co-infection.
Eligibility Criteria
Inclusion Criteria
- are at least age 18, but not older than 70 years old
- have HIV, HCV or both
- do not have HIV, HCV or both, and are having a screening colonoscopy or flexible sigmoidoscopy for abdominal pain or colon cancer screening (control subject)
Exclusion Criteria
- have a history of inflammatory bowel diseases (IBD) or suspected IBD
- have a history of autoimmune diseases including rheumatoid arthritis
- are taking systemic immunomodulators
- are pregnant
Data sourced from ClinicalTrials.gov (NCT01335230). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.